INDINAVIR: 728 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
728
Total FAERS Reports
15 (2.1%)
Deaths Reported
114
Hospitalizations
728
As Primary/Secondary Suspect
16
Life-Threatening
10
Disabilities
Apr 19, 2000
FDA Approved
Discontinued
Status
Active Ingredient: INDINAVIR SULFATE · FDA Application: 020685 ·
First Report: 199407 · Latest Report: 20240401
What Are the Most Common INDINAVIR Side Effects?
#1 Most Reported
Lipodystrophy acquired
195 reports (26.8%)
#2 Most Reported
Eyelid ptosis
158 reports (21.7%)
#3 Most Reported
Mitochondrial toxicity
156 reports (21.4%)
All INDINAVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Lipodystrophy acquired | 195 | 26.8% | 0 | 19 |
| Eyelid ptosis | 158 | 21.7% | 0 | 0 |
| Mitochondrial toxicity | 156 | 21.4% | 0 | 0 |
| Diplopia | 155 | 21.3% | 0 | 0 |
| Virologic failure | 100 | 13.7% | 3 | 19 |
| Drug resistance | 93 | 12.8% | 4 | 9 |
| Viral mutation identified | 93 | 12.8% | 0 | 2 |
| Pathogen resistance | 85 | 11.7% | 0 | 16 |
| Dysphagia | 82 | 11.3% | 0 | 0 |
| Foetal exposure during pregnancy | 76 | 10.4% | 2 | 29 |
| Progressive external ophthalmoplegia | 74 | 10.2% | 0 | 0 |
| Ophthalmoplegia | 58 | 8.0% | 0 | 0 |
| Blood lactic acid increased | 54 | 7.4% | 0 | 12 |
| Treatment failure | 42 | 5.8% | 0 | 0 |
| Drug ineffective | 40 | 5.5% | 1 | 6 |
| Multiple-drug resistance | 39 | 5.4% | 0 | 8 |
| Hypertension | 32 | 4.4% | 0 | 11 |
| Anaemia | 31 | 4.3% | 1 | 8 |
| Dyslipidaemia | 30 | 4.1% | 0 | 8 |
| Fatigue | 28 | 3.9% | 0 | 2 |
Who Reports INDINAVIR Side Effects? Age & Gender Data
Gender: 29.9% female, 70.1% male. Average age: 45.2 years. Most reports from: CA. View detailed demographics →
Is INDINAVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 18 | 0 | 11 |
| 2001 | 29 | 0 | 5 |
| 2002 | 7 | 0 | 2 |
| 2003 | 10 | 1 | 2 |
| 2004 | 8 | 0 | 7 |
| 2005 | 16 | 0 | 0 |
| 2006 | 4 | 0 | 0 |
| 2008 | 7 | 0 | 1 |
| 2009 | 5 | 0 | 0 |
| 2011 | 9 | 0 | 0 |
| 2013 | 1 | 0 | 0 |
| 2014 | 6 | 0 | 0 |
| 2016 | 1 | 0 | 1 |
| 2017 | 4 | 0 | 0 |
| 2018 | 8 | 1 | 4 |
| 2019 | 2 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 6 | 0 | 4 |
| 2022 | 2 | 0 | 0 |
| 2024 | 5 | 0 | 5 |
What Is INDINAVIR Used For?
| Indication | Reports |
|---|---|
| Hiv infection | 536 |
| Product used for unknown indication | 67 |
| Antiretroviral therapy | 44 |
| Acquired immunodeficiency syndrome | 11 |
| Chronic hepatitis c | 5 |
INDINAVIR vs Alternatives: Which Is Safer?
INDINAVIR vs INDOMETHACIN
INDINAVIR vs INDOMETHACIN\INDOMETHACIN
INDINAVIR vs INEBILIZUMAB-CDON
INDINAVIR vs INEXIUM
INDINAVIR vs INFLIXIMAB
INDINAVIR vs INFLIXIMAB-ABDA
INDINAVIR vs INFLIXIMAB-AXXQ
INDINAVIR vs INFLIXIMAB-DYYB
INDINAVIR vs INFLIXIMAB, RECOMBINANT
INDINAVIR vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN
Official FDA Label for INDINAVIR
Official prescribing information from the FDA-approved drug label.